Granular Therapeutics Ltd.

Co-founded by world leading dermatology experts and Medicxi Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologies Vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. Co-founded by Medicxi and several world leading dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Nobel Prize winner Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology), Alys aspires to redefine the landscape of dermatological treatments. The Company is run by co-founder and COO Thibaud Portal (formerly Galderma's Global Head of Prescription Medicines) and Medicxi's Francesco De Rubertis serves as Chairman of the Board. Alys believes that emerging indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements. The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies. Alys is working with leading institutions such as Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology and Empa, the Swiss Federal Laboratories for Materials Science & Technology, demonstrating its commitment to collaborative research and development. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. With more than a dozen active programs, Alys anticipates further organic pipeline growth from its cutting-edge platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses. Over the next three years, the company aims to deliver between seven to ten clinical Proof-of-Concept (POC) readouts, and potentially at least one program to advance to registrational studies. Francesco De Rubertis, Chairman of Alys Pharmaceuticals and Partner at Medicxi commented: "We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology. Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital." Professor John Harris, Chief Innovation Officer of Alys Pharmaceuticals and Chair of Dermatology at UMass Chan Medical School, added: "It is uniquely exciting to oversee such a rich and diverse pipeline, bringing forward modalities that will break new ground in dermatology, including peptides, sophisticated antibodies, or vectorized siRNA." Professor Brian Kim, Vice Chair of Research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, added: "With its diverse pipeline, Alys' commitment to advancing the frontiers of immuno-dermatology has the potential to bring transformative solutions to patients worldwide." About Alys Pharmaceuticals Alys Pharmaceuticals, Inc. ("Alys") is a Boston and Geneva-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders Craig Mello (UMass Chan Medical School), John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder and COO Thibaud Portal. It was formed from the aggregation of 6 asset-centric Medicxi companies – Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. Its pipeline boasts 14 active programs, targeting multiple dermatological indications, including atopic dermatitis, vitiligo, psoriasis and mastocytosis. For further information, please visit . About Medicxi Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: . COI Statement Mount Sinai and Brian Kim, UMass Chan Medical School, Craig Mello and John Harris, Georgia Institute of Technology and Mark Prausnitz, Gustave Roussy and Eric Deutsch, Lars French have financial interests in Alys. SOURCE Alys Pharmaceuticals

Medicxi is pooling assets from six of its companies to form a new drugmaker focused on more than a dozen immuno-dermatology programmes for indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria. The firm, called Alys Pharmaceuticals, has also bagged $100 million in financing from Medicxi.Francesco De Rubertis, a partner at Medicxi who will serve as Alys chairman, said “we believe that bringing together several asset-centric companies…will power up Alys to transform innovation in immuno-dermatology.” De Rubertis noted that Alys’ pipeline, which is based on multiple platform technologies and includes programmes focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma, carries “diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital."Alys combines Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. The drugmaker indicated that over the next three years, it hopes to deliver between seven to 10 clinical proof-of-concept readouts, and potentially at least one programme to advance to registrational studies.The company will be run by co-founder and chief operating officer Thibaud Portal, who formerly served as Galderma's global head of prescription medicines.More to come.

The company will advance dermatological treatments focusing on conditions such as atopic dermatitis. Credit: Andrey_Popov / Shutterstock.com. Alys Pharmaceuticals has announced its launch with a research and development (R&D) immuno-dermatology focused pipeline backed by a $100m financing from Medicxi. Co-founded by Medicxi and a team of dermatology and scientific specialists, Alys Pharmaceuticals is led by co-founder and COO Thibaud Portal, with Medicxi’s Francesco De Rubertis serving as board chairman. The company’s pipeline is powered by multiple platform technologies, targeting a range of dermatological ailments. Its goal is to transform the dermatological treatment landscape, focusing on conditions such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria. Alys Pharmaceuticals’ pipeline also includes programmes for less common ailments such as mastocytosis and cutaneous T-cell lymphoma, and therapies to prevent skin side effects from cancer treatments. See Also: Innovate UK grants funds for breast cancer therapy project LP-410 by Lipella Pharmaceuticals for Graft Versus Host Disease (GVHD): Likelihood of Approval The company is partnering with establishments including the Institut Gustave Roussy and UMass Chan Medical School to advance its collaborative R&D. Alys Pharmaceuticals integrates the platforms and assets from six Medicxi companies: Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, , Klirna Biotech, Nira Biosciences and Vimela Therapeutics. With 14 programmes at an active stage, Alys Pharmaceuticals anticipates significant growth from its new platforms, which cover inflammatory conditions, autoimmune ailments and supportive dermatological care for patients with cancer and rare dermatoses. The company aims to achieve seven to ten clinical proof-of-concept readouts and advance at least one programme to registrational clinical trials in the coming three years. Medicxi partner and Alys Pharmaceuticals chairman Francesco De Rubertis stated: “We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology. “Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital.”